TESTED COMPOUNDS
Telacebec (Q203)
INHIBITORY CONCENTRATION VALUES (MIC/IC50)
MIC = 15 or 7.5 ng/mL
EXPERIMENTAL TECHNIQUE
in vitro & in vivo
LINK TO PUBMED
https://pubmed.ncbi.nlm.nih.gov/32631818/ https://pubmed.ncbi.nlm.nih.gov/34460302/ https://pubmed.ncbi.nlm.nih.gov/32310683/ https://pubmed.ncbi.nlm.nih.gov/32205344/ https://pubmed.ncbi.nlm.nih.gov/32866170/ https://pubmed.ncbi.nlm.nih.gov/30560872
MOLECULAR FORMULA
C29H28ClF3N4O2
2D STRUCTURE
.png)
MOLECULAR WEIGHT
557 µg/mol
PUBCHEM CID
68234908
REFERENCE
Chauffourid, A., Robertid, J., Veziris, N., Aubry, A., Pethe, K., & Jarlier, V. (2020). Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLoS Neglected Tropical Diseases, 14(8), 1?12. https://doi.org/10.1371/JOURNAL.PNTD.0007857 Komm, O., Almeida, D. V., Converse, P. J., Omansen, T. F., & Nuermberger, E. L. (2021). Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer. Antimicrobial Agents and Chemotherapy, 65(11). https://doi.org/10.1128/AAC.01418-21 Scherr, N., Bieri, R., Thomas, S. S., Chauffour, A., Kalia, N. P., Schneide, P., Ruf, M. T., Lamelas, A., Manimekalai, M. S. S., Gr?ber, G., Ishii, N., Suzuki, K., Tanner, M., Moraski, G. C., Miller, M. J., Witschel, M., Jarlier, V., Pluschke, G., & Pethe, K. (2018). Targeting the Mycobacterium ulcerans cytochrome bc 1:aa 3 for the treatment of Buruli ulcer. Nature Communications, 9(1). https://doi.org/10.1038/S41467-018-07804-8 Thomas, S. S., Kalia, N. P., Ruf, M. T., Pluschke, G., & Pethe, K. (2020). Toward a Single-Dose Cure for Buruli Ulcer. Antimicrobial Agents and Chemotherapy, 64(9). https://doi.org/10.1128/AAC.00727-20 Van Der Werf, T. S., Barogui, Y. T., Converse, P. J., Phillips, R. O., & Stienstra, Y. (2020). Pharmacologic management of Mycobacterium ulcerans infection. Expert Review of Clinical Pharmacology, 13(4), 391?401. https://doi.org/10.1080/17512433.2020.1752663